The news of securing a significant award payment and the anticipation of additional grant revenue are positive indicators of financial stability for Plus Therapeutics. This is likely to instill investor confidence in the company's ability to continue operations without the immediate need for additional financing, which can be dilutive to current shareholders. The positive financial outlook may lead to a short-term increase in the stock price.